• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Modified-IL-2 (VIS171) to Preferentially Induce Regulatory T Cells in Nonhuman Primates

September 6, 2024 | Promise of Interleukin-2 Therapy Conference
John J. O’Neil, et al.

Modified-IL-2 (VIS171) to Preferentially Induce Regulatory T Cells in Nonhuman Primates

John J. O’Neil, Davide Schiliró, Joe M. Ladowski, Janghoon Yoon, Angela Park, Rafaela Belloni, Asher D. Schachter, David Oldach, Gregory J. Babcock, Jean Kwun, Stuart Knechtle

© 2025 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design

We use cookies on our website to see how you interact with it. By accepting, you agree to our use of such cookies. Privacy PolicyOk